


Amendments to the claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (*original*) A pharmaceutical composition comprising: a thiourea derivative of formula (I)



or a pharmaceutically acceptable salt thereof; and a cyclodextrin or its derivative,

wherein,

R¹ is hydrogen, fluoro, chloro, methoxycarbonyl, carboxyl or hydroxyaminocarbonyl,

and

R² is hydrogen, methoxy, ethoxy, propoxy, butoxy, isopropoxy, isobutoxy, neopentoxy, methoxymethoxy or benzyloxy.

2. (*original*) The pharmaceutical composition of claim 1, wherein the thiourea derivative is selected from the group consisting of:

1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea,
 1-(4-t-butylbenzyl)-3-(3-chloro-4-methanesulfonylaminobenzyl)thiourea,
 1-(4-t-butylbenzyl)-3-(3-methoxycarbonyl-4-methanesulfonylaminobenzyl)thiourea,
 1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea, and
 1-(4-t-butyl-2-isobutoxybenzyl)-3-(4-methanesulfonylaminobenzyl) thiourea.

3. *(original)* The pharmaceutical composition of claim 1, wherein the thiourea derivative is 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl) thiourea.
4. *(previously presented)* The pharmaceutical composition of claim 1 wherein cyclodextrin or its derivative is present in an amount ranging from 1 to 20 parts by weight per 1 part of the thiourea derivative or the pharmaceutically acceptable salt thereof.
5. *(previously presented)* The pharmaceutical composition of claim 1, wherein the cyclodextrin is of α -, β - or γ -type.
6. *(previously presented)* The pharmaceutical composition of claim 1, wherein the cyclodextrin derivative is selected from the group consisting of 2,6-dimethyl- β -cyclodextrin, 2-hydroxyethyl- β -cyclodextrin, 2-hydroxypropyl- β -cyclodextrin, 2-hydroxyethyl- γ -cyclodextrin, 2-hydroxypropyl- γ -cyclodextrin, (2-carboxymethoxy)propyl- β -cyclodextrin, and sulfobutylether-7- β -cyclodextrin.
7. *(previously presented)* The pharmaceutical composition of claim 1, wherein the cyclodextrin derivative is 2-hydroxypropyl- β -cyclodextrin.
8. *(previously presented)* The pharmaceutical composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable additive.
9. *(original)* The pharmaceutical composition of claim 8, wherein the pharmaceutically acceptable additive is selected from the group consisting of diluents, pH controllers, osmotic controller, buffers, flavors, binders, thickeners, lubricants, preservatives, and a combination thereof.
10. *(previously presented)* The pharmaceutical composition of claim 1, wherein the composition is in the form of a solution containing an inclusion complex prepared by

dissolving the thiourea derivative or the pharmaceutically acceptable salt thereof and cyclodextrin or its derivative in water or a buffer.

11. (*previously presented*) The pharmaceutical composition of claim 1, which comprises a solid inclusion complex prepared by dissolving the thiourea derivative or the pharmaceutically acceptable salt thereof and the cyclodextrin or its derivative in water or a buffer, and subjecting the resulting solution to lyophilization, spray drying, vacuum drying or fluid bed drying to remove water.

12. (*previously presented*) The pharmaceutical composition of claim 1, which comprises a solid inclusion complex and/or a solid dispersion prepared by dissolving the thiourea derivative or the pharmaceutically acceptable salt thereof and the cyclodextrin or its derivative in an organic solvent, and subjecting the resulting solution to lyophilization, spray drying, vacuum drying or fluid bed drying to remove the organic solvent.

13. (*original*) The pharmaceutical composition of claim 12, wherein the organic solvent is ethanol.

14. (*previously presented*) A pharmaceutical formulation comprising the pharmaceutical composition of claim 1 wherein the thiourea derivative of formula (I) is present in an amount being effective for preventing or treating a disease selected from the group consisting of pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, asthma, chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, ferverescence, stomach-duodenal ulcer, and inflammatory diseases.

15. (*currently amended*) The pharmaceutical formulation of claim 14, which is an oral formulation selected from the group consisting of a tablet, pill, powder, granule, solution,

suspension, syrup and capsule.

16. (*currently amended*) The pharmaceutical formulation of claim + 14, which is an injectable solution for intravenous, subcutaneous or intramuscular injection.


17. (*currently amended*) The pharmaceutical formulation of claim + 14, which is a transdermal formulation selected from the group consisting of ointment, cream, lotion, solution, gel, paste, patch and aerosol.

18. (*currently amended*) The pharmaceutical formulation of claim + 14, which is a liquid transocular formulation.

19. (*currently amended*) The pharmaceutical formulation of claim + 14, which is a liquid or powder-type transnasal formulation.

20. (*currently amended*) The pharmaceutical formulation of claim + 14, which is a liquid or semi-solid intravaginal or intrarectal formulation.

21. (*original*) Inclusion complex comprising a thiourea derivative of formula (I)



formula (I)

or a pharmaceutically acceptable salt thereof, and a cyclodextrin or its derivative,

wherein,

R^1 is hydrogen, fluoro, chloro, methoxycarbonyl, carboxyl or hydroxyaminocarbonyl,
and

R^2 is hydrogen, methoxy, ethoxy, propoxy, butoxy, isopropoxy, isobutoxy,
neopentoxo, methoxymethoxy or benzyloxy.

22. (*original*) The inclusion complex of claim 21, wherein the thiourea derivative is selected from the group consisting of:

- 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl)thiourea,
- 1-(4-t-butylbenzyl)-3-(3-chloro-4-methanesulfonylaminobenzyl)thiourea,
- 1-(4-t-butylbenzyl)-3-(3-methoxycarbonyl-4-methanesulfonyl-aminobenzyl)thiourea,
- 1-(4-t-butylbenzyl)-3-(4-methanesulfonylaminobenzyl)thiourea, and
- 1-(4-t-butyl-2-isobutoxybenzyl)-3-(4-methanesulfonylaminobenzyl) thiourea.

23. (*original*) The inclusion complex of claim 21, wherein the thiourea derivative is 1-(4-t-butylbenzyl)-3-(3-fluoro-4-methanesulfonylaminobenzyl) thiourea.

24. (*currently amended*) The inclusion complex of claim 21 , which comprises the cyclodextrin or its derivative in an amount ranging from 1 to 20 parts by weight per 1 part of the thiourea derivative or the pharmaceutically acceptable salt thereof.

25. (*currently amended*) The inclusion complex of claim 21 , wherein the cyclodextrin is of α -, β - or γ -type.

26. (*currently amended*) The inclusion complex of claim 21 , wherein the cyclodextrin derivative is selected from the group consisting of 2,6-dimethyl- β -cyclodextrin, 2-hydroxyethyl- β -cyclodextrin, 2-hydroxypropyl- β -cyclodextrin, 2-hydroxyethyl- γ -cyclodextrin, 2-hydroxypropyl- γ -cyclodextrin, (2-carboxymethoxy)propyl- β -cyclodextrin, and sulfolbutylether-7- β -cyclodextrin.

27. (*currently amended*) The inclusion complex of claim 21 , wherein the cyclodextrin derivative is 2-hydroxypropyl- β -cyclodextrin.

28-30. (*cancelled*)

31. (*currently amended*) Method of treating a mammal including man suffering from the pathological stimulation of VR1 receptors comprising administering to said mammal a therapeutically effective amount of the pharmaceutical composition according to claim 1 .

32. (*original*) Method according to claim 31, wherein the pathological stimulation of VR1 receptors is associated with at least one of the diseases selected from pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, asthma, chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, ferverescence, stomach-duodenal ulcer, and inflammatory diseases.

33-35. (*cancelled*)